HC Wainwright & Co. Maintains Buy on Immunogen, Raises Price Target to $26
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $21 to $26.
August 01, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunogen's price target has been raised from $21 to $26 by HC Wainwright & Co., with a maintained Buy rating.
The raised price target and maintained Buy rating by HC Wainwright & Co. indicates a positive outlook for Immunogen. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100